Dr. Sahoo identified the expression level of CDX2 as a predictive biomarker for favorable response to conventional chemotherapy among stage II colon cancer patients (Dalerba, Sahoo et al. NEJM 2016).
MiDReG tool successfully predicted B cell precursor genes (Sahoo et al. PNAS 2010) and identified a new precursor for B and T cells (Inlay, Bhattacharya, Sahoo et al. Genes Dev 2009)
The lab's Boolean approach have been used to simultaneously identify markers of stem and progenitor cells and prognostic biomarkers in human bladder cancer (Volkmer, Sahoo, Chin et al. PNAS 2012), colon cancer (Dalerba, Kalisky, Sahoo et al. Nat Biotech 2011; Dalerba, Sahoo et al. NEJM 2016), and prostate cancer (Sahoo et al. Oncotarget 2018)